Organogenesis Holdings, Inc. Class A (ORGO)

Organogenesis's stock price has been impacted by several events in the past six months. Strong Q3 2025 financial results and raised full-year guidance initially boosted the stock. A successful FDA meeting and BLA submission plans for ReNu led to a stock surge, although the BLA submission was later delayed. The withdrawal of Medicare LCDs caused the stock price to fall by over 10% due to increased competition. While some executives sold shares, the Chief Administrative and Legal Officer purchased stock, indicating confidence. The company also extended long-term leases for key facilities. Investor alerts were initiated by The Pomerantz Law Firm due to potential securities fraud or unlawful business practices after the Medicare LCD withdrawal.

Analysis of Organogenesis Holdings Inc. stock over the past seven years suggests a seasonal pattern, with a "Buy Date" of August 15 and a "Sell Date" of January 1, historically resulting in a positive geometric average return above the S&P 500 Total Return Index. However, only seven years of data are available, which may be insufficient to create a fully reliable seasonal profile. The company's revenue performance has shown fluctuations, with strong year-over-year growth in Q3 2025 for Advanced Wound Care products, but a decline in overall net product revenue for the first nine months of 2025 compared to 2024. This suggests that while there might be some seasonal trends, other factors like market dynamics and regulatory changes also significantly influence demand and revenue.

Organogenesis Holdings, Inc. is a regenerative medicine company specializing in solutions for advanced wound care, surgical, and sports medicine markets, operating within the biotechnology and healthcare sectors. The company focuses on proprietary regenerative medicine products derived from amniotic tissue, used for wound healing and tissue repair, offering both bioactive and acellular biomaterial products. Its Advanced Wound Care products include Apligraf, Dermagraft, PuraPly AM, Affinity, Novachor, and NuShield, while Surgical and Sports Medicine products include NuShield, PuraForce, Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX. The Advanced Wound Care segment generates the maximum revenue for the company.

Organogenesis has a significant market presence in the advanced wound care segment, serving hospitals, wound care centers, and physician offices. Headquartered in Canton, Massachusetts, with a facility in Smithfield, Rhode Island, the company is expanding internationally in Europe and Asia.

Organogenesis's brand reputation has been affected by regulatory and financial events, including the withdrawal of Medicare Local Coverage Determinations (LCDs), which increased competition and led to a stock price drop and investor alert investigations. These investigations concern potential securities fraud or unlawful business practices, negatively impacting brand perception. Net insider selling over the past quarter has also contributed to negative sentiment, despite some insiders showing confidence through stock purchases.

Organogenesis Holdings Inc. is a publicly traded company with a mix of institutional and individual investors, including 273 institutional owners holding over 74 million shares. Major institutional shareholders include Soleus Capital Management, L.P., Morgan Stanley, First Light Asset Management, LLC, Vanguard Group Inc., Assenagon Asset Management S.A., BlackRock, Inc., Deutsche Bank Ag, Dimensional Fund Advisors Lp and Acadian Asset Management Llc. Significant individual owners include Alan A. Ades, the largest individual shareholder, and insiders such as Dennis Erani, Glenn H. Nussdorf, Albert Erani, and CEO Gary S. Gillheeney, Sr., who collectively hold a substantial portion of the company's stock.